The FDA's acceptance of a single pivotal trial for PMA is a significant regulatory de-risking event for a pre-revenue biotech. Monitor for trial enrollment updates and the Q4 2026 Japan PMDA submission as the next catalysts.
Price Chart
Executive Summary
BioCardia announced FDA confirmation that its ongoing CardiAMP Heart Failure II trial may support a Premarket Approval (PMA) submission for the CardiAMP Cell Therapy System in ischemic HFrEF. This regulatory milestone de-risks the path to market for a therapy targeting a large patient population, but the company remains pre-revenue with no financial data provided in the filing.
Key Facts
- FDA CBER confirmed the ongoing CardiAMP HF II trial may support a PMA for market clearance.
- CardiAMP Cell Therapy has FDA Breakthrough Device designation.
- Japan's PMDA indicated three completed clinical trials likely provide sufficient evidence for approval.
- Upcoming catalyst: Japan PMDA submission targeted for Q4 2026.
- No financial data, revenue, or guidance was disclosed in this filing.
Financial Impact
No financial figures provided; pre-revenue clinical-stage company.
Risk Factors
- Trial may fail to meet endpoints, preventing PMA approval.
- Company has limited liquidity and may need to raise capital to complete the trial.
- Single-trial PMA approvals are rare and FDA may still require additional data.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-019653 |
| Exhibit: ex_972814.htm | 0001437749-26-019653 |
| Document: 0001437749-26-019653-index-headers.html | 0001437749-26-019653 |
| Document: 0001437749-26-019653-index.html | 0001437749-26-019653 |
| Document: 0001437749-26-019653.txt | 0001437749-26-019653 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $0.8975 $1.04 | ▲ +15.88% | ▲ +15.54% | $0.9000 (+0.28%) |
Oct 19, 2026 7d ago | Press Release | $0.9000 $1.04 | ▲ +15.56% | ▲ +15.22% | $0.9000 (−0.00%) |
Oct 7, 2026 19d ago | 8-K | $1.09 $1.06 | ▼ −2.75% | ▼ −2.33% | $0.9000 (−17.43%) |
Oct 1, 2026 25d ago | 8-K | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9000 (−11.76%) |
Oct 1, 2026 25d ago | Press Release | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9000 (−11.76%) |
Sep 23, 2026 4w ago | 8-K | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9000 (−14.29%) |
Sep 23, 2026 4w ago | Press Release | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9000 (−14.29%) |
Sep 10, 2026 6w ago | 8-K | $1.10 $1.08 | ▼ −1.82% | ▼ −2.67% | $0.9000 (−18.18%) |
Aug 24, 2026 9w ago | 8-K | $1.06 $1.13 | ▲ +6.60% | ▲ +6.28% | $0.9000 (−15.09%) |
Aug 5, 2026 11w ago | Press Release | $0.9500 $0.9496 | ▼ −0.04% | ▲ +0.12% | $0.9000 (−5.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers